Chemically modified ribozyme targeting TNF-α mRNA regulates TNF-α and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis

Journal of Clinical Immunology

Volumn 22, Issue 4, 2002, Pages 228-236

  Takahashi, Minako ^a   Funato, Tadao ^a   Suzuki, Yoko ^a   Fujii, Hiroshi ^a   Ishii, Keiko Kumura ^a   Kaku, Mitsuo ^a   Sasaki, Takeshi ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antisense oligonucleotides; Rheumatoid arthritis; Ribozyme; TNF gene

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; NUCLEASE; RIBOZYME; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHEMICAL MODIFICATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; FIBROBLAST CULTURE; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DRUG EFFECT; FIBROBLAST; GENETICS; IMMUNOLOGY; IN VITRO STUDY; METABOLISM; NUCLEOTIDE SEQUENCE; SYNOVIUM;

ARTHRITIS, RHEUMATOID; BASE SEQUENCE; CELLS, CULTURED; FIBROBLASTS; HUMAN; IN VITRO; INTERLEUKIN-6; RNA, CATALYTIC; RNA, MESSENGER; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035996803     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016092909365     Document Type: Article

References (41)

1. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
2. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-α in rheumatoid arthritis
3. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
4. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α
5. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
6. Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis
7. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α
8. Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor-α (cA2) versus placebo in rheumatoid arthritis
9. Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in rheumatoid arthritis
10. Long-term follow-up of changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF α antibody therapy
11. Treatment of rheumatoid arthritis with a recombinant human necrosis factor (p75)-Fc fusion protein
12. The therapeutic effects of an engineered human anti-tumor necrosis factor alpha antibody (CDP571) in rheumatoid arthritis
13. Preformed ribozyme destroys tumor necrosis factor mRNA in human cells
14. Interaction between tumor necrosis factor α ribozyme and cellular proteins. Involvement in ribozyme stability and activity
15. In vivo decay kinetic parameters of hammerhead ribozymes
16. Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase
17. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo
18. Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro
19. Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor-α specific ribozyme in juvenile myelomonocytic leukemic cells
20. Characterization in vitro and in vivo of hammerhead ribozymes directed against murine tumor necrosis factor-α
21. Specific inhibition of macrophage TNF-α expression by in vivo ribozyme treatment
22. Small catalytic RNAs
23. RNA catalysis by a group I ribozyme. Developing a model for transition state stabilization
24. High activity and stability of hammerhead ribozymes containing 2 modified pyrimidine nucleosides and phosphorothioates
25. Minimum ribonucleotide requirement for catalysis by RNA hammerhead domain
26. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance
27. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
28. 1,2-Dioxetanes: Novel chemiluminescent enzyme substrates. Applications to immunoassays
29. Measurement of tumor necrosis factor-α messenger RNA in synovial fibroblasts by real-time quantitative reverse transcriptase-polimerase chain reaction
30. Detection specific polymerase chain reaction product by utilizing the 5 to 3 exonuclease activity of Thermus aquaticus DNA polymerase
31. A novel method for real-time quantitative RT-PCR
32. Identification of the human 26-kD protein, interferon b2, as a B cell hybridoma/plasmacytoma growth factor induced by interleukin-1 and tumor necrosis factor
33. Tumor necrosis factor (cachectin) is an endogeneous pyrogen and induced production of interleukin- 1
34. Blockade of TNF-α with chimeric anti-TNF-α monoclonal antibody, cA2 reduces (IL-6 and IL-8) release in RA MNC cultures. A comparison with IL-1ra
35. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulation factor in rheumatoid synovial effusions
36. Therapeutic application of ribozymes
37. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells
38. Toxicity of cationic lipid-ribozyme complexes in human prostate tumor cells can mimic ribozyme activity
39. Ribozymes: From mechanistic studies to applications in vivo
40. Inhibition of gene expression with ribozymes
41. Chemically modified ribozyme to V gene inhibits anti-DNA production and the formation of immune deposits caused by lupus lymphocytes